Vor Biopharma (VOR) Stock Forecast: StockMap's 2-Week Call

VOR stock forecast: StockMap's model leans Underperform on Vor Biopharma for the two weeks after the Nov 13 close, toward VOR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 0 of 3 two-week windows on VOR since Sep 24; by chance, a call on the same dates was right 51% of the time.

Vor Biopharma last closed at $19.42, +0.52% on the session.

Against the IVW growth benchmark the position is +1.43% over the forecast window.

Vor Biopharma's market cap is $1.19B as of November 13, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -33 (too close to call).

Where VOR sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

23 daily calls for VOR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Vor Biopharma in the 100th percentile on valuation and the 1st percentile on return on equity, where 100 is best.

Vor Biopharma is classified under Health Care / Biotechnology.

StockMap tracks Vor Biopharma as the 125th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.

On that composite Vor Biopharma ranks 270th of 391 in the group, against a group median of -0.24.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 13, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Vor Biopharma (VOR) — StockMap 2-week forecast & tracked accuracy